Endothelial Cell-Based Gene Therapy of Breast Cancer
Abstract
To determine the feasibility of endothelial cell-based gene therapy for metastatic breast cancer, we investigated the optimal dose, toxicity, and efficiency of incorporation of intravenously (IV) -administered, human interleukin-2 gene-modified murine microvascular endothelial cells (hIL-2/MECs) into individual metastatic foci of breast cancer. The objectives of the research are (1) to determine whether intravenously (IV) administered endothelial cells expressing exogenous cytokine gene(s) can selectively migrate into pulmonary metastases of breast tumors, express the cytokine transgene at the metastatic sites, and elicit anti-tumor immune responses, and (2) to determine the safety of IV- administered, genetically-modified endothelial cells. This report covers the investigation of (a) the efficiency of hIL-2/MLEC incorporation at multifocal tumor sites, and (b) the optimal dose and toxicity of IV administration of ML-2/MLECs.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 1999
- Accession Number
- ADB259954
Entities
People
- John O. Ojeifo
Organizations
- Georgetown University